Emerging therapeutic agents for transmissible spongiform encephalopathies: A review

Journal of Veterinary Pharmacology and Therapeutics

Volumn 26, Issue 5, 2003, Pages 315-326

  Koster, T ^a   Singh, K ^b   Zimmermann, M ^a   Gruys, E ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 [(2 AMINOPHENYL)THIO] 4 (2 FURYL)PYRIDINE 3,5 DICARBONITRILE; 4' IODOESORUBICIN; AMPHOTERICIN B; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; COMPLEMENT COMPONENT 3 INHIBITOR; COMPLEMENT INHIBITOR; CONGO RED; CP 60; CRYSAMINE G; DEUTEROPORPHYRIN DERIVATIVE; DEXTRAN DERIVATIVE; ISOPROTEIN; MS 8209; NITRILE; ORGANIC COMPOUND; PENTOSAN POLYSULFATE; PENTOSAN SODIUM POLYSULFATE; PHTHALOCYANINE DERIVATIVE; PHTHALOCYANINE SULFATE; POLYAMIDOAMIDE; POLYANIONIC DEXTRAN SULFATE 500; POLYENE ANTIBIOTIC AGENT; POLYETHYLENEIMINE DERIVATIVE; PORPHYRIN DERIVATIVE; PRION PROTEIN; PRION PROTEIN C; PRION PROTEIN SC; SIRIUS RED; TAVAN; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMYLOIDOSIS; ANTIVIRAL ACTIVITY; CYTOTOXICITY; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG STRUCTURE; DRUG UPTAKE; EXPERIMENTAL MEDICINE; HUMAN; IMMUNIZATION; MOLECULAR MODEL; NONHUMAN; PATHOGENESIS; PLASMA CELL DYSCRASIA; PRION DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STRUCTURE; REVIEW; STRAIN DIFFERENCE;

ANIMALS; DRUGS, INVESTIGATIONAL; PRION DISEASES; PRIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0242551778     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2885.2003.00525.x     Document Type: Review

References (116)

1. Adjou, K.T., Demaimay, R., Lasmézas, C. et al. (1996) Differential effects of a new amphotericin B derivative, MS-8029, on mouse BSE and scrapie: implications for the mechanism of action of polyene antibiotics. Research in Virology, 147, 213-218.
2. Aucouturier, P., Geissmann, F., Damotte, D. et al. (2001) Infected splenic dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie. The Journal of Clinical Investigation, 108, 703-708.
3. Barbieri. B., Giuliani, F.C., Bordoni, T. et al. (1987) Chemical and biological characterization of 4′-iodo-4′-deoxydoxorubicin. Cancer Research, 47, 4001-4006.
4. Barclay, G.R., Houston, E.F., Halliday, S.I. et al. (2002) Comparative analysis of normal prion protein expression on human, rodent, and ruminant blood cells by using a panel of prion antibodies. Transfusion, 42, 517-526.
5. Bartz, J.C., McKenzie, D.I., Bessen, R.A. et al. (1994) Transmissible mink encephalopathy species barrier effect between ferret and mink: PrP gene and protein analysis. Journal of General Virology, 75, 2947-2953.
6. Bolton, D.C., McKinley, M.P. & Prusiner, S.B. (1982) Identification of a protein that purifies with the scrapie prion. Science, 218, 1309-1311.
7. Bossers, A. (1999) Prion diseases: susceptibility and transmissibility. In vivo and in vitro studies with sheep scrapie. PhD Thesis, University of Utrecht, The Netherlands, ISBN 90-393-2108-6.
8. Bossers, A., Schreuder, B.E., Muileman, I.H. et al. (1996) PrP genotype contributes to determining survival times of sheep with natural scrapie. Journal of General Virology, 77, 2669-2673.
9. Brown. K.L., Stewart, K., Ritchie, D.L. et al. (1999) Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells. Nature Medicine, 5, 1308-1312.
10. Brown, D.A., Bruce, M.E. & Fraser. J.R. (2003) Comparison of the neuropathological characteristics of bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD) in mice. Neuropathology and Applied Neurobiology, 29, 262-272.
11. Büeler, H., Fischer, M., Lang, Y. et al. (1992) The neuronal cell surface protein PrP is not essential for normal development and behaviour in mice. Nature, 356, 577-582.
12. Büeler, H., Aguzzi, A., Sailer, A. et al. (1993) Mice devoid of PrP are resistant to scrapie. Cell, 73, 1339-1347.
13. Caspi, S., Halimi, M., Yanai, A. et al. (1998) The anti-prion activity of congo red. Putative mechanism. Journal of Biological Chemistry, 273, 3483-3489.
14. Caughey, B. (2001) Interactions between prion protein isoforms: the kiss of death? Trends in Biochemical Sciences, 26, 235-242.
15. Caughey, B.W., Dong, A., Bhat, K.S. et al. (1991) Secondary structure analysis of the scrapie-associated protein PrP27-30 in water by infrared spectroscopy. Biochemistry, 30, 7672-7680.
16. Caughey, W.S., Raymond, L.D., Horiuchi, M. & Caughey, B. (1998) Inhibition of protease-resistant prion protein formation by porphyrins and phtalocyanines. Proceedings of National Academy of Sciences USA, 95, 12117-12122.
17. Chabry, J., Caughey, B. & Chesebro, B. (1998) Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. Journal of Biological Chemistry, 273, 13203-13207.
18. Cohen, F.E. & Prusiner, S.B. (1998) Pathologic conformations of prion proteins. Annual Review of Biochemistry, 67, 793-819.
19. Collins, S.J., Lewis, V., Brazier, M. et al. (2002) Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Annals of Neurology, 52, 503-506.
20. Come, J.H., Fraser, P.E. & Lansbury, P.T. (1993) A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proceedings of National Academy of Sciences USA, 90, 5959-5963.
21. Creutzfeldt, H.G. (1920) Über eine eigenartige herdförmige Enkrankung des Zentralnervensystems. Zentralblatt f.d. ges. Neurologie u. Psychiatrie, 57, 1-18.
22. DebBurman, S.K., Raymond, G.J., Caughey, B. & Lindquist, S. (1997) Chaperone-supervised conversion of protein to its protease-resistant form. Proceedings of National Academy of Sciences USA, 94, 13938-13943.
23. Dees, C., Wade, W.F., German, T.L. & Marsh, R.F. (1985) Inactivation of the scrapie agent by ultraviolet irradiation in the presence of chlorpromazine. Journal of General Virology, 66, 845-849.
24. Demaimay, R., Adjou, K., Lasmézas, C. et al. (1994) Pharmacological studies of a new derivative of amphotericin B, MS-8029, in mouse and hamster scrapie. Journal of General Virology, 75, 2499-2503.
25. Diringer, H. & Ehlers, B. (1991) Chemoprophylaxis of scrapie in mice. Journal of General Virology, 72, 457-460.
26. Diringer, H., Gelderblom, H., Hilmert, H. et al. (1983) Scrapie infectivity, fibrils and low molecular weight protein. Nature, 306, 476-478.
27. Doh-Ura, K., Iwaki, T. & Caughey, B. (2000) Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. Journal of Virology, 74, 4894-4897.
28. Farquhar, C.F. & Dickinson, A.G. (1986) Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. Journal of General Virology, 67, 463-473.
29. Farquhar, C.F., Dickinson, A.G. & Bruce, M. (1999) Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet, 353, 117.
30. Fauchere, J.L. & Thurieau, C. (1992) Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design. Advances in Drug Research, 23, 127-159.
31. Ford, M.J., Burton, L.J., Morris, R.J. & Hall, S.M. (2002) Selective expression of prion protein in peripheral tissues of the adult mouse. Neuroscience, 113, 177-192.
32. Furukawa, H., Takahashi, M., Nakajima, M. et al. (2002) Prospects of the therapeutic approaches to Creutzfeldt-Jakob disease: a clinical trial of antimalarial, quinacrine. Nippon Rinsho, 60, 1649-1657.
33. Gajdusek, D.C. & Zigas, V. (1959) Kuru. Clinical, pathologic, and epidemiologic study of an acute progressive degenerative disease of the central nervous system among natives of the eastern highlands of New Guinea. American Journal of Medicine, 26, 442-469.
34. Gerstmann, J., Sträussler, E. & Scheinker, I. (1936) Über eine eigenartige hereditar-familiare Erkrankung des Zentralnervensystems zugleich ein Beitrag zur frage des vorzeitigen lokalen Alterns. Zeitschrift Fur Neurologie, 154, 736-762.
35. Gervais, F., Chalifour, R., Garceau, D. et al. (2001) Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid: Journal of Protein Folding Disorder, 8 (Suppl. 1), 28-35.
36. Gianni, L., Bellotti, V., Gianni, A.M. & Merlini, G. (1995) New drug therapy of amyloidoses: resorption of AL-type deposits with 4′-iodo- 4′-deoxydoxorubicin. Blood, 86, 855-861.
37. Goldmann, W., Hunter, N., Martin, T. et al. (1991) Different forms of the bovine PrP gene have five or six short copies of a short, G-C-rich element within the protein-coding exon. Journal of General Virology, 72, 201-204.
38. Goldmann. W., O'Neill, G., Cheung, F. et al. (1999) PrP (prion) gene expression in sheep may be modulated by alternative polyadenylation of its messenger RNA. Journal of General Virology, 80, 2275-2283.
39. Gray, L.E. & Ostby, J.S. (1993) The effects of prenatal administration of azo dyes on testicular development in the mouse: a structure activity profile of dyes derived from benzidine, dimethylbenzidine, or dimethoxybenzidine. Fundamental and Applied Toxicology, 20, 177-183.
40. Haltia, M. (2000) Human prion diseases. Annals of Medicine, 32, 493-500.
41. Hill, A.F., Butterworth, R.J., Joiner, S. et al. (1999) Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet, 353, 183-189.
42. Hölscher, C. Delius, H. & Bürckle, A. (1998) Overexpression of non-convertible PrPc delta 114-121 in scrapie-infected mouse neuroblastoma cells leads to trans-dominant inhibition of wild-type PrP(Sc) accumulation. Journal of Virology, 72, 1153-1159.
43. Hope, J., Morton, L.J.D., Farquhar, C.F. et al. (1986) The major polypeptide of scrapie-associated fibrils (SAF) has the same size, charge distribution and N-terminal protein sequence as predicted for the normal brain protein (PrP). European Molecular Biology Organization Journal, 5, 2591-2597.
44. Horiuchi, M., Chabry, J. & Caughey, B. (1999) Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. European Molecular Biology Organization Journal, 18, 3193-3203.
45. Horiuchi, M., Priola, S., Chabry, J. & Caughey, B. (2000) Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proceedings of National Academy of Sciences USA, 11, 5836-5841.
46. Huang, Z., Prusiner, S.B. & Cohen, F.E. (1996) Scrapie prions: a three-dimensional model of an infectious fragment. Folding Design, 1, 13-19.
47. Hunter, C.L., Lloyd, E., Eltis, L.D. et al. (1997a) Role of the heme propionates in the interaction of heme with apomyoglobin and apocytochrome b5. Biochemistry, 36, 1010-1017.
48. Hunter, N., Goldmann, W., Foster, J.D. et al. (1997b) Natural scrapie and PrP genotype: case-control studies in British sheep. Veterinary Record, 141, 137-140.
49. Ingrosso, L., Ladogana, A. & Pocchiari, M. (1995) Congo red prolongs the incubation period in scrapie-infected hamsters. Journal of Virology, 69, 506-508.
50. Ironside, J.W. & Bell, J.E. (1997) Pathology of prion diseases. In Prion Diseases. Eds Collinge, J. & Palmer, M.S. pp. 57-88. Oxford University Press, London.
51. Josefson, D. (2001) Drugs for malaria and psychosis may offer hope to people with CJD. British Medical Journal, 323, 416.
52. Kaneko, K., Zulianello, L., Scott, M. et al. (1997a) Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proceeding of National Academy of Sciences USA, 94, 10069-10074.
53. Kaneko, K., Wille, H., Mehlorn, I. et al. (1997b) Molecular properties of complexes formed between the prion protein and synthetic peptides. Journal of Molecular Biology, 270, 574-586.
54. Kimura, K.M., Haritani, M., Kubo, M. et al. (2002) Histopathological and immunohistochemical evaluation of the first case of BSE in Japan. Veterinary Record, 151, 328-330.
55. Kirkwood, J.K. & Cunningham, A.A. (1994) Epidemiological observations on spongiform encephalopathies in captive wild animals in the British Isles. Veterinary Record, 135, 296-303.
56. Klein. M.A., Frigg, R., Flechsig, E. et al. (1997) A crucial role for B cells in neuroinvasive scrapie. Nature, 390, 687-690.
57. Klunk, W.E., Debnath, M.L. & Pettegrew, J.W. (1994) Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiology of Aging, 15, 691-698.
58. Kocisko, D.A., Come, J.H., Priola, S.A. et al. (1994) Cell-free formation of protease-resistant prion protein. Nature, 370, 471-474.
59. Kocisko, D.A., Priola, S.A., Raymond, G.J. et al. (1995) Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proceedings of National Academy of Sciences USA, 92, 3923-3927.
60. Korth, C., May, B.C., Cohen, F.E. & Prusiner, S.B. (2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proceedings of National Academy of Sciences USA, 98, 9836-9841.
61. Laplanche, J.L., Chatelain, J., Westaway, D. et al. (1993) PrP polymorphisms associated with natural scrapie discovered by denaturing gradient gel electrophoresis. Genomics, 15, 30-37.
62. Lazarini, F., Deslys, J.P. & Dormont, D. (1992) Variations in prion protein and glial flbrillary acidic protein mRNAs in the brain of scrapie-infected newborn mouse. Journal of General Virology, 73, 1645-1648.
63. Li, S.C., Goto, N.K., Williams, K.A. & Deber, C.M. (1996) Alpha-helical but not beta-sheet propensity of proline is determined by peptide environment. Proceedings of National Academy of Sciences USA, 93, 6676-6681.
64. Liu, H., Farr-Jones, S., Ulyanov, N.B. et al. (1999) Solution structure of Syrian hamster prion protein rPrP(90-231). Biochemistry, 38, 5362-5377.
65. Mabbott, N.A., Bruce, M.E., Botto, M. et al. (2001) Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nature Medicine, 7, 485-487.
66. McKenzie, D., Kaczkowski, J., Marsh, R. & Aiken, J. (1994) Amphotericin B delays both scrapie agent replication and PrP-res accumulation early in injection. Journal of Virology, 68, 7534-7536.
67. McKenzie, D., Bartz, J., Mirwald, J. et al. (1998) Reversibility of scrapie inactivation is enhanced by copper. Journal of Biological Chemistry, 273, 25545-25547.
68. Manetto, V., Medori, R., Cortelli, P. et al. (1992) Fatal familial insomnia: clinical and pathological study of five new cases. Neurology, 42, 312-319.
69. Masullo, C., Macchi, G., Xi, Y.G. & Pocchiari, M. (1992) Failure to ameliorate Creutzfeldt-Jakob disease with AmB therapy. Journal of Infectious Diseases, 196, 784-785.
70. Merlini, G., Ascari, E., Amboldi, N. et al. (1995) Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proceedings of National Academy of Sciences USA, 92, 2959-2963.
71. Merz, P.A., Somerville, R.A., Wisniewski, H.M. & Iqbal, K. (1981) Abnormal fibrils from scrapie-infected brain. Acta Neuropathologica, 54, 63-74.
72. Moore, G.J. (1994) Designing peptide mimetics. Trends in Pharmacological Sciences, 15, 124-129.
73. Nielsen, C.H., Fischer, E.M. & Leslie, R.G.Q. (2000) The role of complement in the acquired immune response. Immunology, 100, 4-12.
74. Pan, K.M., Baldwin, M., Nguyen, J. et al. (1993) Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proceedings of National Academy of Sciences USA, 90, 10962-10966.
75. Parry, H.B. (1983) Historical, clinical, epidemiological, pathological and practical aspects of the natural disease. In Scrapie Disease in Sheep, Ed. Oppenheimer. D.R. pp. 11. Academic Press, London.
76. Pauly, P.C. & Harris, D.A. (1998) Copper stimulates endocytosis of the prion protein. Journal of Biological Chemistry, 273, 33107-33110.
77. Peretz, D., Williamson, R.A., Kaneko, K. et al. (2001) Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature, 412, 739-743.
78. Perrier, V., Wallace, A.C., Kaneko, K. et al. (2000) Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proceedings of National Academy of Sciences USA, 97, 6073-6078.
79. Pocchiari, M., Schmitringer, S., Ladogana, A. & Masullo, C. (1986) Effects of amphotericin B in intracerebrally scrapie inoculated hamster. In Unconventional Virus Diseases of the Central Nervous System, Eds Dormont, D., Court, L.A., Brown, P. & Kingsbury, D.T. pp. 314-323. CEA Ed, Paris.
80. Priola, S.A. & Chesebro, B. (1995) A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells. Journal of Virology, 69, 7754-7758.
81. Prusiner, S.B. (1982) Novel proteinaceous infectious particles cause scrapie. Science, 216, 136-144.
82. Prusiner, S.B. (1991) Molecular biology of prion diseases. Science, 252, 1515-1522.
83. Prusiner, S.B., McKinley, M.P., Bowman, K.A. et al. (1983) Scrapie prions aggregate to form amyloid-like birefringent rods. Cell, 35, 349-358.
84. Riek, R., Hornemann, S., Wider, G. et al. (1996) NMR structure of the mouse prion protein domain PrP(121-231). Nature, 382, 180-182.
85. Riek, R., Wider, G., Billeter, M. et al. (1998) Prion protein NMR structure and familial human spongiform encephalopathies. Proceedings of National Academy of Sciences USA, 95, 11667-11672.
86. Rudyk, H., Vasiljevic, S., Hennion, R.M. et al. (2000) Screening congo red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. Journal of General Virology, 81, 1155-1164.
87. Saborio, G.P., Soto, C., Kascsak, R.J. et al. (1999) Cell-lysate conversion of prion protein into its protease-resistant isoform suggests the participation of a cellular chaperone. Biochemical and Biophysical Research Communications, 258, 470-475.
88. Safar, J., Roller, P.P., Gajdusek, D.C. & Gibbs, C.J. (1993) Thermal stability and conformational transitions of scrapie amyloid (prion) protein correlate with infectivity. Protein Science, 2, 2206-2216.
89. Sakaguchi, S., Katamine, S., Nishida, N. et al. (1996) Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted PrP gene. Nature, 380, 528-531.
90. Sande, M. & Mandell, G.L. (1991) Antimicrobial agents. In The Pharmalogical Basis of Therapeutics. Eds Gilman, A.G., Rall, T.W., Nies, A.S. & Taylor, P. pp. 1117-1145. Pergamon Press, New York.
91. Sassa, S. (1996) Novel effects of heme and heme-related compounds in biological systems. Current Medicinal Chemistry, 3, 273-290.
92. Scott, M., Foster, D., Mirenda, C. et al. (1989) Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell, 59, 847-857.
93. Scott, M.R., Will, R., Ironside, J. et al. (1999) Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proceedings of National Academy of Sciences USA, 96, 15137-15142.
94. Sigurdsson, E.M., Brown, D.R., Daniels, M. et al. (2002) Immunization delays the onset of prion disease in mice. American Journal of Pathology, 161, 13-17.
95. Sigurdsson, E.M., Sy, M.S., Li, R. et al. (2003) Anti-prion antibodies for prophylaxis following prion exposure in mice. Neuroscience Letters, 336, 185-187.
96. Snow, A.D., Choi, P.Y., Cummings, J.A. et al. (2001) Proteoglycans/ glycosaminoglycans in the induction of Alzheimer's amyloid plaque formation and the discovery of natural anti-amyloid agents. IXth International Symposium on Amyloidosis - Abstracts, p. 169.
97. Soto, C. (1999) Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches. Journal of Molecular Medicine, 77, 412-418.
98. Soto, C., Sigurdsson, E.M., Morelli, L. et al. (1998) β-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nature Medicine, 4, 822-826.
99. Soto, C., Kascsak, R.J., Saborio, G.P. et al. (2000) Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides. Lancet, 355, 192-197.
100. Stahl, N., Borchelt, D.R., Hsiao, K. & Prusiner, S.B. (1987) Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell, 51, 229-240.
101. Stylli, S.S., Hill, J.S., Sawyer, W.H. & Kaye, A.H. (1995) Aluminium phthalocyanine mediated photodynamic therapy in experimental malignant glioma. Journal of Clinical Neuroscience, 2, 146-151.
102. Supattapone, S., Nguyen, H.O.B., Cohen, F.E. et al. (1999) Elimination of prions by branched polyamines and implications for therapeutics. Proceedings of National Academy of Sciences USA, 96, 14529-14534.
103. Tagliavini, F., McArthur, R.A., Canciani, B. et al. (1997) Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science, 276, 1119-1122.
104. Sc in vitro. Journal of Molecular Biology, 300, 1309-1322.
105. Tatzelt, J., Prusiner, S.B. & Welch, W.J. (1996) Chemical chaperones interfere with the formation of scrapie prion protein. European Molecular Biology Organization Journal, 15, 6363-6373.
106. Telling, G.C., Parchi, P., DeArmond, S.J. et al. (1996) Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science, 247, 2079-2082.
107. van Keulen, L.J., Schreuder, B.E., Meloen, R.H. et al. (1996) Immunohistochemical detection of prion protein in lymphoid tissues of sheep with natural scrapie. Journal of Clinical Microbiology, 34, 1228-1231.
108. White, A.R., Enever, P., Tayebi, M. et al. (2003) Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature, 422, 80-83.
109. Wilesmith, J.W., Wells, G.A., Cranwell, M.P. & Ryan, J.B. (1988) Bovine spongiform encephalopathy: epidemiological studies. Veterinary Record, 123, 638-644.
110. Will, R.G., Ironside, J.W., Zeidler, M. et al. (1996) A new variant of Creutzfeldt-Jakob disease in the United Kingdom. Lancet, 347, 921-925.
111. Williams, E.S. & Young, S. (1993) Neuropathology of chronic wasting disease of mule deer (Odocoileus hemionus) and elk (Cervus elaphus nelsoni). Veterinary Pathology, 30, 36-45.
112. Williams, A., Lucassen. P.J., Ritchie, D. & Bruce, M. (1997) PrP deposition, microglial activation, and neuronal apoptosis in murine scrapie. Experimental Neurology, 14, 433-438.
113. Wuthrich, K. & Riek, R. (2001) Three-dimensional structures of prion proteins. European Molecular Biology Organization Journal 20, 703-712.
114. Wyatt, J.M., Pearson, G.R., Smerdon, T.N. et al. (1991) Naturally occurring scrapie-like spongiform encephalopathy in five domestic cats. Veterinary Record, 129, 233-236.
115. Xi, Y.G., Ingrosso, L., Ladogana, A. et al. (1992) Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Nature, 356, 598-601.
116. Yang, D.S., Serpell, L.C., Yip, C.M. et al. (2001) Assembly of Alzheimer's amyloid-β fibrils and approaches for therapeutic intervention. Amyloid: Journal of Protein Folding Disorder, 8 (Suppl. 1), 10-19.